CVAC Stock Overview
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
Price History & Performance
|Historical stock prices|
|Current Share Price||US$24.48|
|52 Week High||US$133.00|
|52 Week Low||US$23.09|
|1 Month Change||-40.37%|
|3 Month Change||-40.26%|
|1 Year Change||-75.61%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-56.21%|
Recent News & Updates
A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of CureVac N.V...
CureVac: Wait For Concrete News Before Investing
In the same way as Moderna and BioNTech, CureVac makes use of mRNA to develop COVID vaccines. However, in contrast to these two illustrious peers which are at commercialization stage, CureVac's first generation vaccine candidate has exhibited a much lower efficiency against infection. Following the August 31 update on CVnCoV, the biotech still makes for an investment case as it is developing a second generation vaccine and is also diversified on cancer cures. The cash position is also good. However, in view of past deceptions around efficacy, it is better to wait for concrete news before purchasing the stock.
|CVAC||US Biotechs||US Market|
Return vs Industry: CVAC underperformed the US Biotechs industry which returned -14.3% over the past year.
Return vs Market: CVAC underperformed the US Market which returned 13.7% over the past year.
|CVAC Average Weekly Movement||10.4%|
|Biotechs Industry Average Movement||10.0%|
|Market Average Movement||6.6%|
|10% most volatile stocks in US Market||15.9%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: CVAC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: CVAC's weekly volatility (10%) has been stable over the past year.
About the Company
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens.
CureVac Fundamentals Summary
|CVAC fundamental statistics|
Is CVAC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CVAC income statement (TTM)|
|Cost of Revenue||€175.25m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.50|
|Net Profit Margin||-690.10%|
How did CVAC perform over the long term?See historical performance and comparison
Is CureVac undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CVAC ($24.48) is trading above our estimate of fair value ($10.9)
Significantly Below Fair Value: CVAC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CVAC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CVAC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CVAC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CVAC is overvalued based on its PB Ratio (5.8x) compared to the US Biotechs industry average (2.2x).
How is CureVac forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CVAC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: CVAC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CVAC's is expected to become profitable in the next 3 years.
Revenue vs Market: CVAC's revenue (4.7% per year) is forecast to grow slower than the US market (9.3% per year).
High Growth Revenue: CVAC's revenue (4.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CVAC's Return on Equity is forecast to be very high in 3 years time (275.1%).
How has CureVac performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CVAC is currently unprofitable.
Growing Profit Margin: CVAC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CVAC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CVAC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CVAC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: CVAC has a negative Return on Equity (-67.3%), as it is currently unprofitable.
How is CureVac's financial position?
Financial Position Analysis
Short Term Liabilities: CVAC's short term assets (€1.5B) exceed its short term liabilities (€814.1M).
Long Term Liabilities: CVAC's short term assets (€1.5B) exceed its long term liabilities (€153.8M).
Debt to Equity History and Analysis
Debt Level: CVAC has more cash than its total debt.
Reducing Debt: Insufficient data to determine if CVAC's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CVAC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CVAC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is CureVac current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CVAC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CVAC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CVAC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CVAC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CVAC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Franz-Werner Haas (51 yo)
Dr. Franz-Werner Haas, LLD, LLM, PhD, has been Chief Executive Officer of CureVac AG since June 2020 and has been its Chief Operating Officer since 2018 and also serves as its Member of Management Board. H...
CEO Compensation Analysis
Compensation vs Market: Franz-Werner's total compensation ($USD687.47K) is below average for companies of similar size in the US market ($USD6.40M).
Compensation vs Earnings: Franz-Werner's compensation has increased whilst the company is unprofitable.
Experienced Management: CVAC's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: CVAC's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.9%.
CureVac N.V.'s employee growth, exchange listings and data sources
- Name: CureVac N.V.
- Ticker: CVAC
- Exchange: NasdaqGM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$7.669b
- Shares outstanding: 186.83m
- Website: https://www.curevac.com
Number of Employees
- CureVac N.V.
- Friedrich-Miescher-Strasse 15
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/16 23:07|
|End of Day Share Price||2022/01/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.